Background
Methods
Study setting
Study Design
Ethics statement
Results
Characteristics of all health facilities included in the Lablite cross-sectional baseline survey
Description of health systems organization of all health facilities
Malawi | Uganda | Zimbabwe | ||||||
---|---|---|---|---|---|---|---|---|
Primary (n = 16) | Secondary (n = 3) | Tertiary (n = 1) | Primary (n = 21) | Secondary (n = 16) | Tertiary (n = 2) | Primary (n = 16) | Secondary (n = 6) | |
Owner | ||||||||
Public/MoH1
| 12 (75) | 2 (66) | 1 (100) | 20 (95) | 12 (75) | 2 (100) | 12 (75) | 5 (83) |
Private not for profit2
| 4 (25) | 1 (33) | 0 (0) | 1 (5) | 4 (25) | 0 (0) | 4 (25) | 1 (17) |
Charges for out-patient consultations | ||||||||
No | 12 (75) | 2 (66) | 1 (100) | 21 (100) | 11 (69) | 2 (100) | 4 (25) | 0 (0) |
Yes | 4 (25) | 1 (33) | 0 (0) | 0 (0) | 5 (31) | 0 (0) | 12 (75) | 6 (100) |
Location | ||||||||
Urban | 2 (13) | 1 (33) | 1 (100) | 3 (14) | 4 (25) | 2 (100) | 2 (13) | 1 (17) |
Peri-urban | 3 (19) | 1 (33) | 0 (0) | 3 (14) | 6 (38) | 0 (0) | 1 (6) | 0 (0) |
Rural | 11 (69) | 1 (33) | 0 (0) | 15 (71) | 6 (38) | 0 (0) | 13 (81) | 5 (83) |
Access road | ||||||||
Tarmac | 3 (19) | 1 (33) | 1 (100) | 1 (5) | 6 (38) | 1 (50) | 12 (75) | 6 (100) |
Functioning dirt road | 13 (81) | 2 (66) | 0 (0) | 20 (95) | 9 (56) | 1 (50) | 4 (25) | 0 (0) |
Water transport | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (6) | 0 (0) | 0 (0) | 0 (0) |
Catchment population: Median (range) | 29,275 (11,074-240,000) | 50,015 (29,721-1,897,168) | 5,490,000 | 9,000 (325–210,000) | 70,295 (2,400-500,000) | 2,250,000 (1,500,000-3,000,000) | 8,616 (3,122-113,000) | 13,747 (9,184-298,495) |
Time (hours) to nearest tertiary facility: Median (range) | 1.9 (.33-6) | 1.5 (.25-5) | - | 1.5 (.33-3.5) | 1.3 (.25-2) | |||
Physicians | 0 (0–0) | 2.8 (1.5-4) | 0 (0–0) | 2 (1–4.5) | 5.5 (5–6) | 0 (0–0) | 1 (1–1) | |
Clinical Officers/Medical Assistants | 1 (1–2) | 25 (11–40) | 2 (1–2) | 4.5 (2–8) | 19 (8–29) | 0 (0–0) | 1 (0–1) | |
Midwives/Nurses | 2.5 (1–4.5) | 42 (34–49) | 309 | 4 (3–6) | 22 (13–68) | 99 (59–138) | 6 (2.5-14) | 66 (46–82) |
Counsellors | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–1) | 0 (0–0) | 1 (1–1) | 4 (3–4) | |
Laboratory technicians/assistants3
| 0 (0–0.5) | 4.5 (3–6) | 1 (0–1) | 2 (1.8-3) | 8.5 (8–9) | 0 (0–0) | 3 (2–4) | |
Auxiliary staff4
| 5 (3.5-7.5) | 70 (40–101) | 2 (0–3) | 6 (0–8) | 57 (13–100) | 3 (3–9) | 64 (52–93) | |
Community health workers | 18 (11–22) | 31 (21–40) | 0 (0–0) | 0 (0–3) | 2 (0–4) | 0 (0-.5) | 0 (0–0) | |
Administrative staff | 0 (0–2) | 7 (3–11) | 0 (0–1) | 1 (.5-6) | 10 (7–13) | 0 (0–0) | 13 (6–18) |
Availability of clinical and laboratory services at all health facilities
Malawi | Uganda | Zimbabwe | ||||||
---|---|---|---|---|---|---|---|---|
Primary (n = 16) | Secondary (n = 3) | Tertiary (n = 1) | Primary (n = 21) | Secondary (n = 16) | Tertiary (n = 2) | Primary (n = 16) | Secondary (n = 6) | |
Clinical services
| ||||||||
Adult medical care | 16 (100) | 3 (100) | 1 (100) | 21 (100) | 16 (100) | 2 (100) | 15 (94) | 6 (100) |
Paediatric medical care | 16 (100) | 3 (100) | 1 (100) | 20 (95) | 16 (100) | 2 (100) | 14 (88) | 6 (100) |
Antenatal care | 15 (94) | 3 (100) | 1 (100) | 21 (100) | 16 (100) | 2 (100) | 16 (100) | 6 (100) |
Obstetric care | 12 (75) | 3 (100) | 1 (100) | 18 (86) | 16 (100) | 2 (100) | 16 (100) | 6 (100) |
Family planning | 13 (81) | 2 (67) | 1 (100) | 21 (100) | 15 (94) | 2 (100) | 15 (100) | 5 (83) |
TB treatment | 16 (100) | 3 (100) | 1 (100) | 17 (81) | 16 (100) | 2 (100) | 14 (88) | 6 (100) |
HIV testing and counselling | 16 (100) | 3 (100) | 1 (100) | 21 (100) | 16 (100) | 2 (100) | 16 (100) | 6 (100) |
PMTCT | 15 (94) | 3 (100) | 1 (100) | 21 (100) | 16 (100) | 2 (100) | 16 (100) | 6 (100) |
DNA PCR for infant diagnosis (off site)1
| 9 (82) | 3 (100) | 1 (100) | 14 (67) | 13 (81) | 2 (100) | 13 (100) | 5 (100) |
Cotrimoxazole prophylaxis for HIV positive patients | 15 (94) | 3 (100) | 1 (100) | 19 (90) | 16 (100) | 2 (100) | 16 (100) | 6 (100) |
Isoniazid preventative therapy for HIV positive patients | 6 (38) | 1 (33) | 1 (100) | 6 (29) | 6 (38) | 2 (100) | 1 (6) | 3 (50) |
Antiretroviral therapy | 9 (56) | 3 (100) | 1 (100) | 6 (29) | 16 (100) | 2 (100) | 15 (94) | 6 (100) |
Laboratory services
| ||||||||
Haemoglobin | 6 (38) | 3 (100) | 1 (100) | 9 (43) | 16 (100) | 2 (100) | 2 (13) | 5 (83) |
Malaria diagnosis (rapid or microscopy) | 8 (50) | 3 (100) | 1 (100) | 16 (76) | 16 (100) | 2 (100) | 13 (81) | 5 (83) |
Sputum microscopy for TB | 6 (38) | 2 (67) | 1 (100) | 15 (71) | 16 (100) | 2 (100) | 1 (6) | 6 (100) |
CSF microscopy | 0 (0) | 3 (100) | 1 (100) | 2 (10) | 10 (63) | 2 (100) | 1 (6) | 4 (67) |
Cryptococcal diagnosis (Ag or microscopy) | 0 (0) | 3 (100) | 1 (100) | 2 (10) | 11 (69) | 2 (100) | 1 (6) | 6 (100) |
Blood culture | 0 (0) | 1 (33) | 1 (100) | 0 (0) | 1 (6) | 0 (0) | 0 (0) | 3 (50) |
Chest x-ray | 1 (6) | 3 (100) | 1 (100) | 0 (0) | 9 (56) | 2 (100) | 0 (0) | 4 (67) |
Availability of key commodities for routine HIV care in all health facilities
Malawi | Uganda | Zimbabwe | ||||||
---|---|---|---|---|---|---|---|---|
Primary | Secondary | Tertiary | Primary | Secondary | Tertiary | Primary | Secondary | |
(n = 16) | (n = 3) | (n = 1) | (n = 21) | (n = 16) | (n = 2) | (n = 16) | (n = 6) | |
Antibiotics
| ||||||||
No. facilities with stock-outs | 5/16 | 1/3 | 0/1 | 17/21 | 6/16 | 2/2 | 4/16 | 0/6 |
No. days/90 per facility if >0 | 14,14,30,60,60 | 30 | 14,14,14,21,30,30,30,30,35,42,59,60,60,60,70,75,90 | 7,10,14,21,28,30 | 14,30 | 5,7,90,90 | ||
TB drugs
| ||||||||
No. facilities with stock-outs | 1/16 | 1/3 | 0/1 | 9/17 | 2/16 | 1/2 | 2/14 | 1/6 |
No. days/90 per facility if >0 | 2 | 30 | 7,14,14,15,30,31,60,60,90 | 31,90 | 30 | 3,60 | 14 | |
Anti-malarial drugs
| ||||||||
No. facilities with stock-outs | 2/16 | 0/3 | 0/1 | 3/21 | 2/16 | 0/2 | 1/16 | 0/6 |
No. days/90 per facility if >0 | 5,7 | 14,14,14 | 21,30 | 7 | ||||
HIV test kits
| ||||||||
No. facilities with stock-outs | 10/16 | 1/3 | 0/1 | 5/21 | 4/16 | 1/2 | 2/16 | 0/6 |
No. days/90 per facility if >0 | 3,8,14,14,14, 18,23,25,30, 30 | Days missing | 3,14,30,30,30 | 5,7,21,90 | 1 | 4,7 | ||
Cotrimoxazole for HIV positive patients
| ||||||||
No. facilities with stock-outs | 11/15 | 0/3 | 0/1 | 8/19 | 4/16 | 0/2 | 1/16 | 1/6 |
No. days/90 per facility if >0 | 14,21,31,45,60,60,66,70,90,90,90 | 20,21,60,60,66,90,90,90 | 28,30,60,90 | 7 | 90 | |||
ART for PMTCT
| ||||||||
No. facilities with stock-outs | 2/15 | 2/3 | 1/1 | 3/21 | 1/16 | 0/2 | 0/16 | 0/6 |
No. days/90 per facility if >0 | 14,60 | 7,90 | 62 | 2,14,60 | 31 | |||
Adult ART
| ||||||||
No. facilities with stock-outs | 0/9 | 1/3 | 0/1 | 0/6 | 0/16 | 0/2 | 1/1 | 1/6 |
No. days/90 per facility if >0 | 30 | 30 | 14 | |||||
Paediatric ART
| ||||||||
No. facilities with stock-outs | 2/9 | 0/3 | 0/1 | 3/6 | 3/16 | 0/2 | 2/6 | |
No. days/90 per facility if >0 | 1,7 | 14,90,90 | 14,30,60 | 14,40 |
Characteristics of health facilities with on-site ART provision available
ART service availability and utilization at health facilities
Malawi | Uganda | Zimbabwe | |||||||
---|---|---|---|---|---|---|---|---|---|
Primary | Secondary | Tertiary | Primary | Secondary | Tertiary | Primary | Secondary | ||
(n = 9) | (n = 3) | (n = 1) | (n = 6) | (n = 16) | (n = 2) | (n = 151) | (n = 6) | ||
Provision start year2
| |||||||||
2003-04 | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 3 (20) | 2 (100) | 0 (0) | 0 (0) | |
2005-06 | 1 (11) | 1 (33) | 0 (0) | 2 (33) | 12 (80) | 0 (0) | 2 (13) | 3 (50) | |
2007-08 | 3 (33) | 2 (66) | 0 (0) | 2 (33) | 0 (0) | 0 (0) | 4 (27) | 2 (33) | |
2009-10 | 2 (22) | 0 (0) | 0 (0) | 1 (17) | 0 (0) | 0 (0) | 7 (47) | 1 (17) | |
2011 | 3 (33) | 0 (0) | 0 (0) | 1 (17) | 0 (0) | 0 (0) | 2 (13) | 0 (0) | |
Days service provided | |||||||||
1/fortnight | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 14 (93) | 0 (0) | |
1-2/week | 8 (89) | 2 (66) | 0 (0) | 3 (50) | 4 (25) | 0 (0) | 0 (0) | 1 (17) | |
3-4/week | 1 (11) | 0 (0) | 0 (0) | 1 (17) | 3 (19) | 1 (50) | 0 (0) | 0 (0) | |
5/week | 0 (0) | 1 (33) | 1 (100) | 2 (33) | 9 (56) | 1 (50) | 1 (7) | 5 (100) | |
Adults ≥15 on ART3,4
| 516 (241–886) | 2610 (2,438-9,600) | 17,453 | 189 (56–604) | 576 (385–890) | 1,968 (1,523-2,412) | 203 (97–359) | 2,800 (1,976-3,726) | |
Adults ≥15 initiating ART per month4
| 49 (30–55) | 37 (25–478) | 597 | 11 (7–19) | 25 (12–34) | 66 (35–97) | 13 (6–20) | 50 (40–100) | |
Children on ART3,4
| 22 (9–51) | 44 (21–59) | 230 (223–237) | 19 (10–31) | 203 (165–318) | ||||
Children initiating ART per month4
| 4 (1–7) | 7 (5–23) | 27 | 1.5 (1–5) | 3 (2–5) | 3.5 (2–5) | 2.5 (1–4.5) | 5 (3–10) |
ART drug regimen utilization: Adults, Paediatric and PMTCT regimens
Availability of laboratory services for monitoring treatment toxicity at health facilities with on-site ART provision
Availability and utilization of CD4 and viral load testing for monitoring treatment effectiveness in health facilities providing ART
Malawi | Uganda | Zimbabwe | |||||||
---|---|---|---|---|---|---|---|---|---|
Primary | Secondary | Tertiary | Primary | Secondary | Tertiary | Primary | Secondary | ||
(n = 9) | (n = 3) | (n = 1) | (n = 6) | (n = 16) | (n = 2) | (n = 15) | (n = 6) | ||
CD4 testing regularly used prior to initiation
| |||||||||
In all patients | 0 | 1 | 1 | 1 | 4 | 0 | 9 | 2 | |
Selected patients1
| 4 | 2 | 0 | 4 | 11 | 2 | 4 | 3 | |
Not used regularly | 5 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | |
CD4 monitoring on ART in adults
| |||||||||
Every 3 months | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
Every 6 months | 0 | 0 | 0 | 5 | 11 | 2 | 10 | 2 | |
Every 12 months | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | |
If clinically indicated | 3 | 1 | 0 | 0 | 2 | 0 | 1 | 1 | |
Not used regularly | 6 | 2 | 1 | 0 | 1 | 0 | 2 | 1 | |
CD4 monitoring on ART in children
| |||||||||
Every 3 months | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
Every 6 months | 0 | 0 | 0 | 4 | 11 | 1 | 9 | 3 | |
Every 12 months | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | |
If clinically indicated | 3 | 1 | 0 | 0 | 2 | 0 | 1 | 1 | |
Not used regularly | 6 | 2 | 1 | 0 | 1 | 0 | 2 | 1 | |
Viral load monitoring on ART
| |||||||||
If clinically indicated | 1 | 0 | 1 | 0 | 1 | 2 | 1 | 0 | |
Not used regularly | 8 | 3 | 0 | 6 | 15 | 0 | 14 | 6 |
Malawi | Uganda | Zimbabwe | |||||||
---|---|---|---|---|---|---|---|---|---|
Primary | Secondary | Tertiary | Primary | Secondary | Tertiary | Primary | Secondary | ||
All facilities | (n = 2) | (n = 1) | (n = 1) | (n = 4) | (n = 14$) | (n = 1) | (n = 7) | (n = 6) | |
CD4s per month | 84 (77–91) | 57 | 831 | 40 (27–141) | 82 (19–152) | 388 | 10 (6–30) | 171 (12–312) | |
Adults* on ART | 201; missing | 9,600 | 17,453 | 189 (74–705) | 576 (336–874) | 2,412 | 263 (129–1,845) | 2,800 (1,976-3,726) | |
Adults initiating ART per month | 46 (40–52) | 478 | 597 | 11 (7–22) | 27 (12–34) | 35 | 13 (6–20) | 50 (40–100) | |
Facilities where adults initiating ART per month <5% total adults* on ART | (n = 0) | (n = 1) | (n = 1) | (n = 2) | (n = 9$$) | (n = 1) | (n = 4) | (n = 5) | |
Estimated frequency of CD4s in adults* on ART** | |||||||||
At least 6-monthly | 0 | 0 | 2 | 2 | 0 | 0 | 0 | ||
Every 6 months to 1 year | 0 | 0 | 0 | 2 | 1 | 0 | 1 | ||
Every 1 to 2 years | 0 | 1 | 0 | 2 | 0 | 1 | 1 | ||
Less than once every 2 years | 1 | 0 | 0 | 3 | 0 | 3 | 3 |